Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Diversity of Antigen Receptors

Diversity of Antigen Receptors

Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Development of a LASSO-based machine learning model for relapse prediction in lupus nephritis.

Lupus science & medicine·2026

Same author

Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas.

The New England journal of medicine·2026

Same author

Late cytopenia after CD19 chimeric antigen receptor T cell in large B cell lymphoma: A Cell Therapy Consortium Analysis.

Blood advances·2026

Same author

Elevated ST2<sup>+</sup> Tregs in RA-ILD: correlation with pulmonary fibrosis and the IL-33/ST2/AREG axis.

Arthritis research & therapy·2026

Same author

Mechanistic studies on the regulation of systemic sclerosis progression by imbalance in angiogenic T cell subsets.

Journal of autoimmunity·2026

Same author

Characteristics and clinical significance of aortic ulcer signs on computed tomography angiography in patients with Takayasu's arteritis.

Clinical and experimental rheumatology·2026

Search research articles

Related Experiment Video

Updated: May 31, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Chimeric Antigen Receptor Therapy for B-cell Malignancies.

David L Porter¹, Michael Kalos, Zhaohui Zheng

¹1. Abramson Cancer Center, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, 19104, USA.

Journal of Cancer

|July 1, 2011

Summary

Chimeric antigen receptor T-cell therapy (CART-19) with 4-1BB signaling domains shows significant in-vivo expansion and potent anti-tumor activity in refractory chronic lymphocytic leukemia (CLL) patients. These modified cells persist long-term and effectively target tumor sites.

Keywords:

B-cell Malignancies CART-19 Chimeric Antigen Receptor Therapy

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Related Experiment Videos

Last Updated: May 31, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Area of Science:

Immunotherapy
Oncology
Cellular therapy

Background:

Chronic lymphocytic leukemia (CLL) is often refractory to conventional chemotherapy.
Novel therapeutic strategies are needed for patients with relapsed or refractory CLL.

Purpose of the Study:

To evaluate the in-vivo efficacy of CART-19 cells engineered with a 4-1BB signaling domain.
To assess the expansion, persistence, tumor trafficking, and anti-leukemic activity of these modified cells.

Main Methods:

Administration of CART-19 cells expressing the 4-1BB signaling domain to chemotherapy-refractory CLL patients.
Monitoring of in-vivo cellular expansion, tumor site trafficking, and long-term persistence.
Assessment of anti-tumor activity and clinical response.

Main Results:

Unprecedented and massive in-vivo expansion of CART-19 cells was observed.
Effective trafficking of CART-19 cells to tumor sites was demonstrated.
Long-term persistence of CART-19 cells in vivo was achieved.
Rapid and potent anti-tumor activity was induced in patients.

Conclusions:

CART-19 cells engineered with the 4-1BB signaling domain exhibit robust expansion and persistence in vivo.
These modified T-cells demonstrate significant anti-leukemic activity in refractory CLL.
The 4-1BB signaling domain enhances the efficacy of CART-19 therapy for CLL.